Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Sulphasalazine in ulcerative colitis: in memoriam?

Literature DB >> 1674925

Sulphasalazine in ulcerative colitis: in memoriam?

J Hayllar¹, I Bjarnason.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 1991 PMID： 1674925 PMCID： PMC1378915 DOI： 10.1136/gut.32.5.462

Source DB: PubMed Journal: Gut ISSN： 0017-5749 Impact factor: 23.059

× No keyword cloud information.

26 in total

1. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis.

Authors: J H BARON; A M CONNELL; J E LENNARD-JONES; F A JONES
Journal: Lancet Date: 1962-05-26 Impact factor: 79.321

2. Effect of sulphasalazine and its metabolites on mitogen induced transformation of lymphocytes--clues to its clinical action?

Authors: P Sheldon; C Webb; K A Grindulis
Journal: Br J Rheumatol Date: 1988-10

3. Exacerbation of diarrhoea and pain in patients treated with 5-aminosalicylic acid for ulcerative colitis.

Authors: C A Austin; P A Cann; T H Jones; C D Holdsworth
Journal: Lancet Date: 1984-04-21 Impact factor: 79.321

4. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.

Authors: U Klotz; K Maier; C Fischer; K Heinkel
Journal: N Engl J Med Date: 1980-12-25 Impact factor: 91.245

5. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.

Authors: K M Das; M A Eastwood; J P McManus; W Sircus
Journal: N Engl J Med Date: 1973-09-06 Impact factor: 91.245

6. The effect of sulfasalazine and its active components on human polymorphonuclear leukocyte function in relation to ulcerative colitis.

Authors: L Molin; O Stendahl
Journal: Acta Med Scand Date: 1979

7. Capacity-limited gut wall metabolism of 5-aminosalicylic acid, a therapeutically active metabolite of sulfasalazine, in rats.

Authors: H J Pieniaszek; T R Bates
Journal: J Pharm Sci Date: 1979-10 Impact factor: 3.534

8. Effects of sulphasalazine and its metabolites on prostaglandin synthesis, inactivation and actions on smooth muscle.

Authors: J R Hoult; P K Moore
Journal: Br J Pharmacol Date: 1980-04 Impact factor: 8.739

9. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

Authors: A K Azad Khan; D T Howes; J Piris; S C Truelove
Journal: Gut Date: 1980-03 Impact factor: 23.059

10. Comparative nephrotoxicity of aspirin and phenacetin derivatives.

Authors: I C Calder; C C Funder; C R Green; K N Ham; J D Tange
Journal: Br Med J Date: 1971-11-27

12 in total

1. Sulphasalazine in ulcerative colitis.

Authors: A S Michalowski
Journal: Gut Date: 1992-11 Impact factor: 23.059

Review 2. Clinical pharmacology and therapeutics.

Authors: R C Horton; M J Kendall
Journal: Postgrad Med J Date: 1991-12 Impact factor: 2.401

Review 3. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.

Authors: Yongjun Wang; Claire E Parker; Tania Bhanji; Brian G Feagan; John K MacDonald
Journal: Cochrane Database Syst Rev Date: 2016-04-21

4. Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.

Authors: N Mahmud; D G Weir; D Kelleher
Journal: Ir J Med Sci Date: 1999 Oct-Dec Impact factor: 1.568